Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study.

This post hoc subgroup analysis of POLARIX evaluated the efficacy and safety of Pola-R-CHP vs R-CHOP in older patients aged ≥60, ≥65, ≥70, and ≥75 years.

这项对POLARIX的事后亚组分析评估了Pola-R-CHP与R-CHOP在年龄≥60岁、≥65岁、≥70岁和≥75岁老年患者中的疗效和安全性。

As of 15 June 2022 (median follow-up, 40 months), 629 patients aged ≥60 years were included (Pola-R-CHP, n = 311; R-CHOP, n = 318).

截至2022年6月15日（中位随访时间为40个月），共有629名年龄≥60岁的患者被纳入研究（Pola-R-CHP组，n=311；R-CHOP组，n=318）。

Clinically meaningful improvements in PFS with Pola-R-CHP vs R-CHOP were observed across all age groups, particularly in patients aged ≥70 years whereby the risk of disease progression, relapse, or death was reduced by 37% (unstratified hazard ratio[HR], 0.63; 95% confidence interval[CI], 0.41-0.96).

在所有年龄组中，与R-CHOP相比，Pola-R-CHP在无进展生存期（PFS）方面显示出临床上有意义的改善，特别是在≥70岁的患者中，疾病进展、复发或死亡的风险降低了37%（未分层风险比[HR]，0.63；95%置信区间[CI]，0.41-0.96）。

In patients aged ≥60 years, overall survivalwas similar with Pola-R-CHP vs R-CHOP (unstratified HR, 0. 99; 95% CI, 0.67-1.47).

在≥60岁的患者中，Pola-R-CHP与R-CHOP的总生存期相似（未分层的HR为0.99；95%置信区间为0.67-1.47）。

Safety profiles were similar for Pola-R-CHP vs R-CHOP among patients aged ≥60 years, including rates of grade 3 to 4 adverse events (AEs; 62.7% vs 61.5%), grade 3 to 5 infections (15.0% vs 12.9%), and grade 5 AEs (3.6% vs 3.2%); no novel toxicities were reported.

在≥60岁的患者中，Pola-R-CHP与R-CHOP的安全性特征相似，包括3至4级不良事件（AEs）的发生率（62.7%对61.5%）、3至5级感染的发生率（15.0%对12.9%）和5级AEs的发生率（3.6%对3.2%）；没有报告新的毒性。

Incidenceof grade 3 to 4 febrile neutropenia was higher with Pola-R-CHP than R-CHOP (16.3% vs 7.6%), highlighting the importance of granulocyte colony-stimulating factor prophylaxis in older patients receiving Pola-R-CHP.

与 R-CHOP 相比，Pola-R-CHP 的 3 至 4 级发热性中性粒细胞减少症的发生率更高（16.3% 对 7.6%），这突显了在接受 Pola-R-CHP 治疗的老年患者中使用粒细胞集落刺激因子预防的重要性。

The benefit-risk profile favored Pola-R-CHP vs R-CHOP in older patients with previously untreated DLBCL.

在之前未治疗的弥漫性大 B 细胞淋巴瘤老年患者中，Pola-R-CHP 的获益-风险比优于 R-CHOP。

This trial was registered at www.ClinicalTrials.gov as #NCT03274492.

该试验已在www.ClinicalTrials.gov注册，注册号为#NCT03274492。